ChromoCure announced yesterday that its long-held theory of cancer, aneuploidy, has been further validated by a study published in the January 15, 2010 issue of Cancer Research (Volume 70, Issue 2). The authors that are affiliated with the Department of Molecular Oncology and Analytic Microscopy Core Facility, H. Lee Moffitt Cancer Center and Research Institute and Cancer Biology Graduate Program, University of South Florida, Tampa, Florida, concluded that "Evidence is offered for the hypothesis that the early, founding effects of B-Raf mutations on melanoma development occur initially through aneuploidy, before the benefits of activated B-Raf to transformed cell growth and survival can accrue."
Further validation of the chromosomal theory of cancer, a theory long championed by ChromoCure has given the company hope and they continue to work towards their theory.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the worldwide gold standard for cancer detection, therapy and cure research.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
